Warfarin is a drug widely used for oral anticoagulation in patients with atrial fibrillation, venous thromboembolism or a prosthetic heart valve to reduce the risk of thromboembolic events [1] . The optimal warfarin dose is assessed by measuring the international normalized ratio (INR), which should be kept within a narrow range, since the risk of thromboembolic events decreases with an increasing INR, while the risk of bleeding events increases. A large inter-and intra-patient variability in warfarin dose requirement makes frequent INR monitoring necessary. The required dosage is influenced by several factors, such as gender, age, diet, concomitant medication and genetic factors.
Polymorphisms in both the CYP2C9 gene, encoding for the main metabolizing enzyme, cytochrome P450 2C9 (CYP2C9), and the VKORC1 gene, encoding the target enzyme vitamin K epoxide reductase multiprotein complex 1, explain approximately a third of the variation in warfarin dose requirement. Information regarding the genotype of a patient can therefore be used to predict the warfarin maintenance dose. Although the ability of genotype-guided dosing to improve the safety and efficacy of warfarin treatment has been investigated in a few small randomized controlled trials, there is still no clear evidence about the effectiveness of this dosing strategy [2] .
The economic impact of genotyping patients prior to warfarin use is also not clear. Results from cost-effectiveness analyses of warfarin pharmacogenetics (using genetic information to determine the required dose) do not all point in the same direction [3] [4] [5] . In one of these studies genotyping appeared to be the dominant strategy, meaning that genotyping was more effective and less costly than not genotyping [4] . By contrast, other studies found that the gain in effectiveness was coupled with higher costs [3, 5] . In most studies the effect of genotyping was based directly on its observed or assumed impact on the risk of bleeding and thromboembolic 
Summary of methods & results
In their study Meckley et al. developed a decision analytic Markov model to perform an economic evaluation comparing genotypeguided dosing with standard anticoagulation care using a lifetime horizon [1] . The base-case scenario focused on 65-year-old patients with atrial fibrillation who were initiated on long-term treatment with warfarin. Patients were stratified by genotype into three different groups: the first group consisted of CYP2C9 wild-type/VKORC1 wild-type patients, the second of CYP2C9 wild-type/VKORC1 variant patients, and in the last group were the CYP2C9 variants. This last group was not stratified by VKORC1 genotype for group size reasons. All patients entered the Markov model in a healthy ('well') state and could move from this state to the states 'clot', 'bleed', 'sequelae' or 'death' in monthly cycles. The probabilities to experience a major bleeding or thromboembolic event were based on the time spent within, above or below therapeutic INR range. The time patients spent within, above and below therapeutic INR range was based on data from the COUMAGEN trial [6] . This trial provided data on the difference in time spent in therapeutic INR range between the genotype-guided dosing group and the standard dosing group, but the authors reanalyzed the COUMAGEN data in order to obtain additional information regarding the time spent above or below this range. The differences in time spent within the different INR ranges between the two dosing strategies were used in the model for the first month and reduced to zero in the sixth month of therapy. An increased bleeding risk of 2.26, independent of the effect of INR, was assumed from a meta-analysis for the CYP2C9 variant patients, which was subjected to sensitivity ana lysis [7] .
Utility (or quality-of-life) scores for the different health states were used to calculate the difference in quality-adjusted life-years (QALYs) between the standard and the genotype-guided dosing group. Genotyping itself was assumed to have no effect on the quality of life of the patient. The difference in costs between the two strategies was calculated and included only direct medical costs, since the authors applied a third party payer perspective. One-way sensitivity analyses were performed for all input parameters over prespecified ranges and several scenario analyses were conducted. The chance that the incremental cost-effectiveness ratio (ICER) would fall below a certain willingness-to-pay threshold (e.g., US$50,000 per QALY gained) was calculated in a probabilistic sensitivity analysis using Monte Carlo simulations.
Meckley et al. found that pharmacogenetics could reduce the time spent above therapeutic INR range in the CYP2C9 variant group by 15%, and the time spent below therapeutic range in the CYP2C9 wild-type/VKORC1 wild-type group by 8% [1] . In the third group (CYP2C9 wild-type/VKORC1 variants) there were no differences in time spent above or below therapeutic INR range between the two dosing strategies. In the base case ana lysis the incidence of bleedings was reduced by 0.17%, the incidence of thromboembolic events increased by 0.03% and incidence of death reduced by 0.13% in the pharmacogenetic-guided dosing group. These differences resulted in a QALY increase of 0.0027. As genotyping also led to an overall cost increase of US$162, the ICER was US$60,725 per QALY gained. When looking at the ICERs in the different genotype groups, pharmacogeneticguided dosing was most cost effective in the group consisting of VKORC1 and CYP2C9 wild-type patients. In this group there was a decrease in the risk of bleedings, thromboembolic events and deaths. The ICER for this group was US$13,500 per QALY gained. For the patients with CYP2C9 variant alleles genotypeguided dosing was dominated by the standard dosing strategy, meaning that genotyping resulted in a decrease in QALYs and an increase in costs. This result arose because of an increase in the frequency of thromboembolic events in this group.
The uncertainty around the cost of a pharmacogenetic test, as investigated in the one-way sensitivity ana lysis, caused the largest part of the uncertainty around the cost-effectiveness ratio. In one of the scenario analyses, data from Caraco et al. were used instead of data from the COUMAGEN trial [8] . In this scenario, the genotyping strategy was the dominant strategy. Genotyping was also the dominant strategy when it was assumed that genotyping reduced the bleeding risk in CYP2C9 variant patients further. The probabilistic sensitivity ana lysis revealed that there was a 15% chance that the pharmacogenetic-guided dosing was the dominant strategy. In addition, it was estimated that there was a 46% chance that the true ICER was below US$50,000 per QALY gained and a 67% chance that it was below US$100,000 per QALY gained.
Discussion
This study suggested that pharmacogenetic-guided dosing of warfarin could improve the health of patients initiating warfarin while also increasing healthcare costs compared with a standard dosing regimen. The probability that genotyping would cost less than US$50,000 per QALY gained was estimated to be almost 50%. However, owing to uncertainty regarding the values of several input parameters, Meckley et al. found that the possible impact of genotyping ranged from a possibility that genotype-guided dosing is the dominant strategy to a possibility that it is less effective and more costly than a standard dosing regimen [1] . This wide range of possible realities is mainly due to uncertainty regarding the effectiveness of pharmacogenetic-guided dosing on the risk of serious adverse events or therapeutic failure of warfarin therapy.
Patients with a variant genotype have a higher risk of bleedings due to warfarin therapy, because of a lower dose requirement. A genotype-guided dosing strategy might reduce this risk when patients with a variant genotype receive a lower dose. It is, therefore, remarkable that genotyping appeared to be less cost effective in patients with a variant genotype. This was explained by the increase in the number of thromboembolic events in this group, which might indicate that the dosages for these patients were overadjusted.
Since the clinical trials performed to date provide no direct evidence regarding the influence of genotyping on the incidence of adverse events or therapeutic failure, these authors used the time within, above and below therapeutic INR range as a surrogate for these clinical end points. This method has been used in two other studies investigating the cost-effectiveness of pharmacogeneticguided dosing of warfarin [5, 9] . In the study of Patrick et al., data from the COUMAGEN trial [6] together with data from Caraco et al. [8] were used to calculate the effect of genotyping on the time spent within therapeutic INR range [9] . In a probabilistic sensitivity ana lysis Patrick et al. found a chance of 42% that genotyping would be cost effective given a willingness to pay of $50,000 per QALY [9] , which is quite similar to the 46% in the study of Meckley et al. [1] . In the study of You et al. this chance was 38% [5] and the base case results were also less optimistic than in the Meckley et al. study [1] , since they reported an ICER of $347,059 per QALY gained. In the study by You et al. lower baseline adverse event rates were used and the effect of geno typing was not stratified by genotype as in the current study. In the probabilistic sensitivity ana lysis by Meckley et al. the costs of the genetic test are also varied [1] . It would have been more useful to vary this parameter in a scenario ana lysis, because at the moment of decision-making the prices will be known already.
The development of this model using INR as a surrogate end point for bleedings and thromboembolic events seems very useful, as there is not enough evidence about the effect of genotyping on the adverse event rate. However, the uncertainty around the results of this study are still too large to allow any recommendations regarding the implementation of pharmacogenetics in treatment with warfarin. This uncertainty is mainly caused by the fact that there is not sufficient evidence regarding the effect of genotyping on INR ranges either, because this has only been investigated in a few small clinical trials. For some input parameters, such as the effect of genotyping on INR after the first month of therapy, the authors needed to make assumptions, because there is no evidence yet available on these parameters. Therefore, it is necessary to delay any recommendations regarding genotyping until more data from large clinical trials become available.
Expert commentary & five-year view
Pharmacogenetic-guided dosing of warfarin and other coumarin derivatives seems to be a promising new method to improve the safety and efficacy of oral anticoagulant therapy. Currently, the response to warfarin treatment is evaluated by INR measurement after the first few days of therapy. The prescribed dose can then be adapted to the patient's needs, so the patient will receive a more individualized dose after this first INR measurement. However, in the first few days of therapy, no information on the patient's response is available, so all patients receive the same loading dose. If patients were to be genotyped before they started taking warfarin, the loading dose for the first few days could already be personalized. However, this would only be possible if the genotype results are available before warfarin initiation. Therefore, it is desirable to have a fast, reproducible and accurate method to genotype; for this purpose, point-of-care testing might be useful.
Meckley et al. have shown that pharmacogenetic-guided dosing could improve health at higher healthcare costs compared with standard care, but there is not enough information available yet on the effectiveness of this genotype-guided dosing method [1] . Moreover, as the study of You et al. [5] demonstrates, a low adverse event rate with warfarin therapy will make genotyping less cost effective. As a consequence, the cost-effectiveness of pharmacogenetic-guided warfarin dosing will differ between countries and will be particularly favorable in settings where warfarin therapy is complicated by a relatively high rate of bleedings and thromboembolic events. The upcoming use of direct thrombin inhibitors might also reduce the value of genotype-guided warfarin dosing in the future to some extent.
It is not yet fully known how to use the genetic information to adjust the prescribed warfarin dose. In the study of Meckley et al. it seemed that patients with a variant genotype were underdosed in the pharmacogenetic-guided dosing strategy [1] . Dosing algorithms, such as the dosing algorithm developed by the International Warfain Pharmacogenetics Consortium [10] , therefore need to be developed and tested widely to find the optimal way of adjusting the dose of warfarin or other coumarin derivatives according to the genetic information. It is also not yet clear whether the genetic information has any value for determining the right dose after the first few days of therapy, when the dose is also adjusted according to the INR values of the patients.
Within a few years, more data on this subject will become available, as several large clinical trials investigating the effectiveness of pharmacogenetic-guided dosing algorithms in treatment with warfarin and other coumarin derivatives are now underway [11, 101] . Since the primary outcome of these studies is time within therapeutic INR range, a model like the one presented in this study of Meckley et al. [1] would be very useful to assess not only the effectiveness but also the cost-effectiveness of a pharmacogenetic-guided dosing strategy.
Key issues
• Polymorphisms in the CYP2C9 and VKORC1 genes can explain a large part of the variation in dose requirement of warfarin.
• Pharmacogenetic-guided dosing might improve the safety and efficacy of warfarin treatment, because sub-or supra-therapeutic dosages put patients at increased risk of thromboembolic events or bleedings.
• Genotype-guided dosing has been shown to improve health, but also increase healthcare costs.
• A large uncertainty remains around the effectiveness of genotyping patients prior to warfarin treatment, as well as around the economic consequences of this strategy.
• Data from large clinical trials are necessary to reduce this uncertainty.
